Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOCC-2
- Development stage
- Phase 1
- Lead developer
- Xiamen Encheng Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SOCC-2 is an investigational small molecule potassium-competitive acid blocker (P-CAB) developed by Xiamen Encheng Pharmaceutical for the treatment of acid-related gastrointestinal disorders. It functions by reversibly inhibiting the gastric H+/K+-ATPase (the proton pump) through competition with potassium ions. Unlike traditional proton pump inhibitors (PPIs), SOCC-2 does not require acid activation and provides a more rapid onset of action with sustained acid suppression. The drug is being evaluated for indications including gastroesophageal reflux disease (GERD), duodenal ulcers, gastric ulcers (including those associated with NSAIDs), and Helicobacter pylori infection.
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on SOCC-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOCC-2.